Episode 433: Yes, more diabetes trials

In episode 433, Mike and James get all sweet on the latest diabetic trials from 2019. We provide the results, the critique and the context and we do it all with our usual level of charm and wit – which is by all accounts at a level similar to the size of the effect that many diabetes medications have on CVD events. 

Show notes

Diabetes trials synopsis

Comments

excellent talk, per usual! do you think results are generalizable to whole class or would you stick w/ specific agent. Say for SGLT2s, would you choose canaglflozin for ckd & dabigliflozin for HF, etc. Say formularly restrictions prefferred empa-, would it be reasonable to think/hope that benefits would be seen across class?